SCHEMBL4696104

SCHEMBL4696104

Oc1cc(-c2ccncc2Cl)c(-c2ccc(C(F)(F)F)cc2)nn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.44
CNR2 P34972 2/20 0.44
KIF11 P52732 1/20 0.41
NPC1 O15118 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
KLRK1 P26718 4/20 0.38
MICA Q29983 4/20 0.38
RAET1L Q5VY80 4/20 0.38
RPS6KA3 P51812 1/20 0.38
GPBAR1 Q8TDU6 4/20 0.36
SLC22A12 Q96S37 2/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
MAPK1 P28482 1/20 0.35
MAP2K4 P45985 1/20 0.35
MAPKAPK2 P49137 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4689605 0.87 CNR1 (0.46) CNR1CNR2KIF11NPC1ALDH1A1
SCHEMBL4745691 0.77 CNR1 (0.51) CNR1CNR2KIF11NPC1ALDH1A1
SCHEMBL4695159 0.77 CNR1 (0.53) CNR1CNR2KIF11NPC1ALDH1A1
SCHEMBL4695173 0.76 CNR1 (0.51) CNR1CNR2HTT
SCHEMBL14545460 0.75 CNR1 (0.49) CNR1CNR2
SCHEMBL1042340 0.74 SRC (0.45) KIF11ALDH1A1MAPK1MAP2K4MAPKAPK2
SCHEMBL1043394 0.74 KIF11 (0.50) KIF11ALDH1A1
SCHEMBL14545735 0.74 CNR1 (0.52) CNR1CNR2MAPTGPBAR1
SCHEMBL5515993 0.74 CNR1 (0.42) CNR1CNR2KLRK1MICARAET1L
SCHEMBL14545736 0.73 CNR1 (0.50) CNR1CNR2SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1871762-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2008-01-02 EP disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
WO-2006113704-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078135-A1 Substituted heteroaryl CB1 antagonists CNR1, CNR2, OPRL1 CNR1 1/4885CNR2 2/4885KIF11 4642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.